Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control

Current data on the use of irreversible electroporation (IRE) in the treatment of prostate cancer (PCa) is limited. We aim to evaluate the safety, short-term functional and oncological outcomes of focal IRE in low-intermediate risk PCa.

Between February 2013 and May 2014, 32 consecutive men underwent IRE at a single centre. Patients with low-intermediate risk PCa who had not received previous PCa treatment were included for analysis. The tumour was ablated using 3-6 electrodes, ensuring a minimum 5-mm safety margin around the visible magnetic resonance imaging (MRI) lesion. Follow-up included recording Clavien complications, Expanded Prostate Cancer Index Composite (EPIC) questionnaires (baseline, 1. 5, 3, 6 months), 6-month multi-parametric MRI (mp-MRI) and 7-month biopsy. Findings on mp-MRI and biopsy were sub-divided into infield, adjacent or outfield of the treatment zone.

Twenty-five men were included for final analysis. Safety follow-up revealed one Clavien Grade 3 complication and five Grade 1 complications. Functional follow-up confirmed no significant change in American Urological Association urinary symptom score, sexual or bowel function. Infield, there were no suspicious findings on mp-MRI (n=24) or biopsy (n=21) in all patients. Adjacent to the treatment zone, five (21%) had suspicious findings on mp-MRI with four (19%) proving to be significant on biopsy. Outfield, there were two (8%) with suspicious findings on mp-MRI and one (5%) significant finding on biopsy. For the five patients with significant findings on follow-up biopsy, one is awaiting repeat IRE, one had radical prostatectomy and three remained on active surveillance.

In selected patients with low-intermediate risk PCa, focal IRE appears to be safe with minimal morbidity. There were no infield recurrences and 76% of patients were histologically free of significant cancer at 8 months. Almost all recurrences were adjacent to the treatment zone, and this was addressed by widening the treatment margins. Prostate Cancer and Prostatic Diseases advance online publication, 13 October 2015; doi:10. 1038/pcan. 2015. 47.

Prostate cancer and prostatic diseases. 2015 Oct 13 [Epub ahead of print]

F Ting, M Tran, M Böhm, A Siriwardana, P J Van Leeuwen, A-M Haynes, W Delprado, R Shnier, P D Stricker

St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia. , St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia. , Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia. , St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia. , St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia. , Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia. , Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia. , Southern Radiology, Randwick, NSW, Australia. , St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe